Table 3.
Basic characteristics of patients with NHL from the study sample
| Basic demographic & clinical characteristics | 3-weekly regimens (n=28)a |
Dose dense regimens (n=11)b |
All regimens (n=39) |
|---|---|---|---|
| Age range (years) | 18-64 | 20-61 | 18-64 |
| IPI low, n (%) | 7 (25) | 4 (36) | 11 (28) |
| IPI low/intermediate, n (%) | 11 (39) | 3 (27) | 14 (36) |
| IPI high/intermediate, n (%) | 5 (18) | 1 (9) | 6 (15) |
| IPI high, n (%) | 5 (18) | 3 (27) | 8 (21) |
| Ann Arbor stade III/IV, n (%) | 21 (75) | 8 (73) | 29 (74) |
| Prior/concomitant radiotherapy, n (%) | 2 (7) | 0 | 2 (5) |
Basic demographic and clinical characteristics of the patients with NHL are presented for all 3-weekly chemotherapy regimens, for dose-dense regimens (R-ACVBP-14, ACVBP, R-CHOP-14 and R-etoposide, cyclophosphamide), and for all regimens.
a 3-weekly regimens were R-CHOP-21 (n = 13), CHOP-21 (n = 3), BVAM (n = 2), R-DHAP (n = 2), R-GEMOX (n = 2), R-COPADEM (n = 2) and Hyper CVAD, ESHAP, methotrexate/vincristine/ifosfamide/dexamethasone, R-ICE (1 patient each).
b Dose-dense regimens were R-ACVBP-14 (n = 6), ACVBP (n = 2), R-CHOP-14 (n = 2) and R-etoposide-cyclophosphamide (n = 1)